Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai to Conduct More Collaborative Multinational Clinical Trials
April 28, 2008
- NEW PRODUCTS
April 28, 2008
- Ono to Place Top Priority on Development in US
April 28, 2008
- Ain Pharmaciez to Negotiate Price for Each Product
April 28, 2008
- AZ to Stop JUPITER Study Due to Unequivocal Evidence of Benefits
April 28, 2008
- BUSINESS NEWS IN BRIEF
April 28, 2008
- Prof. Yamanaka Comments on Bayer Yakuhin Team's Reported Achievements with Human iPS Cells
April 28, 2008
- Generic Makers to Embark on Mergers, Tie-ups: Mr Sawai
April 21, 2008
- NCC to Take Full Advantage of New System to Provide Advanced Healthcare to More Patients
April 21, 2008
- Doctors Should Collect Information Themselves when Using Generics: Prof. Ogata
April 21, 2008
- Further Spread of Hepatitis C Viral Infections Unlikely: Chugai Seminar
April 21, 2008
- Korosho to Punish Healthcare Providers Who Don't Try to Use More Generics: Mr Nakagaki
April 21, 2008
- Drug Cost Cut by 6% by Generic Substitution in 1st Week of April: Nihon Chouzai
April 21, 2008
- New Prescription Form Is Working Well: Mr Takeda
April 21, 2008
- No More Than 10% of Prescriptions Will Be Substituted with Generics: Dr Muto
April 21, 2008
- PMDA Should Support R&D from Patients' Viewpoints: New PMDA Chief Executive
April 21, 2008
- Opinions Split on Whether Only Pharmacists Should Be Allowed to Manage Stores
April 21, 2008
- TOPICS／Q&A Issued on GL on Drugs Using Autologous Cells
April 21, 2008
- OPINION／How to Get Lucky in Your Pharma Career
April 21, 2008
- LDP Begins Discussions on the Need for a Japanese Version of FDA
April 21, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…